Compare BEDU & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEDU | VNRX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 38.2M |
| IPO Year | 2017 | N/A |
| Metric | BEDU | VNRX |
|---|---|---|
| Price | $2.21 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.17 |
| AVG Volume (30 Days) | 7.4K | ★ 2.8M |
| Earning Date | 01-23-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $224,321,752.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | N/A | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $1.35 | $0.27 |
| 52 Week High | $2.28 | $0.94 |
| Indicator | BEDU | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 31.94 |
| Support Level | $2.18 | $0.28 |
| Resistance Level | $2.20 | $0.31 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 60.00 | 3.40 |
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.